Drug intelligence / Profile preview

lumefantrine + lopinavir + ritonavir

Development stage: Preclinical
Lead developer: Abbott
Modality: Small Molecules
Administration: Oral

Overview

This represents a drug interaction scenario rather than a single formulated product. When artemether-lumefantrine (antimalarial) is co-administered with lopinavir/ritonavir (HIV treatment), significant pharmacokinetic interactions occur. Lopinavir/ritonavir inhibits CYP3A4 enzymes, resulting in substantially increased lumefantrine exposure (5-10 fold) while decreasing artemether exposure. This interaction is clinically relevant for HIV patients requiring malaria treatment.

Targets

CYP3A4 (Cytochrome P450 3A4)PR (Progesterone receptor)

Beyond the preview

Go deeper on lumefantrine + lopinavir + ritonavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lumefantrine + lopinavir + ritonavir.

Explore the full profile